Inventiva (IVA) Income from Continuing Operations (2019 - 2021)
Inventiva (IVA) recorded quarterly Income from Continuing Operations of 10229081.59 in Q2 2021, down 34.44% quarter-over-quarter from 7608937.39 in Q1 2021, and down 5.72% on a YoY basis from 10850198.4 in Q2 2020.
Inventiva (IVA) Income from Continuing Operations (2019 - 2021) Analysis & Trends
Inventiva's Income from Continuing Operations history runs 3 years deep, the most recent figure standing at 10229081.59 for Q2 2021.
- In Q2 2021, Income from Continuing Operations fell 5.72% year-over-year to 10229081.59; the TTM figure through Jun 2021 stood at 62967175.71 (changed N/A YoY), while the FY2025 annual figure was 198387936.21, down 0.95% from the prior year.
- Income from Continuing Operations was 10229081.59 for Q2 2021 at Inventiva, down from 7608937.39 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 7475875.08 in Q1 2020 to a low of 35453930.96 in Q4 2020.
- Historically, Income from Continuing Operations has averaged 17304279.35 across 3 years, with a median of 9952153.68 in 2020.
- The sharpest annual moves came in 2020 and 2021: Income from Continuing Operations decreased 6.2% in 2020, then fell 1.78% in 2021.
- A 3-year view of Income from Continuing Operations shows it stood at 33382625.32 in 2019, then retreated by 6.2% to 35453930.96 in 2020, then jumped by 71.15% to 10229081.59 in 2021.
- The last three Income from Continuing Operations figures came in at 10229081.59 (Q2 2021), 7608937.39 (Q1 2021), and 35453930.96 (Q4 2020), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -56.48 Mn |
| 10 | Inventiva | 8.93 Mn | -259.80 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | -10.23 Mn |
| Mar 31, 2021 | -7.61 Mn |
| Dec 31, 2020 | -35.45 Mn |
| Jun 30, 2020 | -9.68 Mn |
| Mar 31, 2020 | -7.48 Mn |
| Dec 31, 2019 | -33.38 Mn |